Clinical Trial Update: A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update indicating withdrawal of a study evaluating BMS-824393 in combination with peginterferon alfa-2a and ribavirin for treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-824393
• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C Virus Genotype 1 | Phase 2 | Status: WITHDRAWN